AstraZeneca's PCT application covers anti-PD-L1 antibody combinations with chemotherapy agents and optionally a PARP inhibitor for treating endometrial cancer.

Patentradars sammanfattning

This PCT application (WO 2025/037273) from AstraZeneca discloses methods and compositions for treating endometrial cancer by combining an anti-PD-L1 antibody (or antigen-binding fragment) with one or more chemotherapy agents, with optional inclusion of a PARP inhibitor. The IPC codes encompass taxane/epothilone-class agents (A61K 31/337), pyrimidine-based chemotherapeutics (A61K 31/502), platinum compounds (A61K 33/243), and therapeutic antibodies (A61K 39/395), indicating a multi-modal regimen. The claims target both general cancer (A61P 35/00) and leukemia/hematological malignancies (A61P 35/02) but with endometrial cancer as the primary indication. Priority is claimed from three US provisional applications filed between August 2023 and May 2024.

AI-genererad och redaktionellt processad.